Paper36768445
Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents.
Kim M and 4 others. Int J Mol Sci, 2023. Cited by 18 papers, by iCite.
Cite this record
ConductScience Library. Re-Sensitizing Cancer Stem Cells to Conventional Chemotherapy Agents. Papers, record 36768445. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36768445
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Endothelial Cells | |
| Signal Transduction | |
| Neoplastic Stem Cells | |
| Tumor Microenvironment |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| (Grant No. AP14872052) | Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan | PubMed |
Source PubMed
References196
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 29651130 | Targeting the tumour stroma to improve cancer therapy. | Nat Rev Clin Oncol | 2018 | https://conductscience.org/library/papers/29651130 | PubMed |
| 2 | 22367781 | Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. | Mol Cancer Ther | 2012 | https://conductscience.org/library/papers/22367781 | PubMed |
| 3 | 29693169 | Nodal induced by hypoxia exposure contributes to dacarbazine resistance and the maintenance of stemness in melanoma cancer stem‑like cells. | Oncol Rep | 2018 | https://conductscience.org/library/papers/29693169 | PubMed |
| 4 | 20530696 | Targeting Notch to target cancer stem cells. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20530696 | PubMed |
| 5 | 26264352 | The Notch pathway in colorectal cancer. | Int J Cancer | 2016 | https://conductscience.org/library/papers/26264352 | PubMed |
| 6 | 30397178 | Long Noncoding RNA LBCS Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of SOX2. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30397178 | PubMed |
| 7 | 30536571 | Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. | Mol Oncol | 2019 | https://conductscience.org/library/papers/30536571 | PubMed |
| 8 | 19915977 | Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. | Breast Cancer Res Treat | 2010 | https://conductscience.org/library/papers/19915977 | PubMed |
| 9 | 21983179 | Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. | Carcinogenesis | 2011 | https://conductscience.org/library/papers/21983179 | PubMed |
| 10 | 25749420 | Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. | Cancer Lett | 2015 | https://conductscience.org/library/papers/25749420 | PubMed |
| 11 | 12042769 | The fundamental role of epigenetic events in cancer. | Nat Rev Genet | 2002 | https://conductscience.org/library/papers/12042769 | PubMed |
| 12 | 31792354 | Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. | Nat Rev Clin Oncol | 2020 | https://conductscience.org/library/papers/31792354 | PubMed |
| 13 | 32586404 | Inhibition of Notch pathway enhances the anti-tumor effect of docetaxel in prostate cancer stem-like cells. | Stem Cell Res Ther | 2020 | https://conductscience.org/library/papers/32586404 | PubMed |
| 14 | 25691811 | Hedgehog signaling in cancer stem cells: a focus on hematological cancers. | Stem Cells Cloning | 2015 | https://conductscience.org/library/papers/25691811 | PubMed |
| 15 | 31910865 | A pre-existing population of ZEB2+ quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. | J Exp Clin Cancer Res | 2020 | https://conductscience.org/library/papers/31910865 | PubMed |
| 16 | 23369605 | Mechanisms of chemoresistance in cancer stem cells. | Clin Transl Med | 2013 | https://conductscience.org/library/papers/23369605 | PubMed |
| 17 | 30251117 | Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells. | Mol Cell Biochem | 2019 | https://conductscience.org/library/papers/30251117 | PubMed |
| 18 | 27194046 | Epigenetic Determinants of Cancer. | Cold Spring Harb Perspect Biol | 2016 | https://conductscience.org/library/papers/27194046 | PubMed |
| 19 | 19664991 | DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. | Cell Stem Cell | 2009 | https://conductscience.org/library/papers/19664991 | PubMed |
| 20 | 31368411 | Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma. | Ther Adv Respir Dis | 2019 | https://conductscience.org/library/papers/31368411 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42897654 | Single-cell RNA sequencing reveals that TAF7 promotes colorectal cancer stemness by targeting SOX2. | Biol Direct | 2026 | https://conductscience.org/library/papers/42897654 | PubMed |
| 42586960 | Translational insights and clinical challenges of targeting cancer stem cells. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42586960 | PubMed |
| 42293745 | Metabolic reprogramming and plasticity of cancer stem cells. | Front Cell Dev Biol | 2026 | https://conductscience.org/library/papers/42293745 | PubMed |
| 41622398 | From Signaling Pathways to Combination Therapy: Bioactive Compounds against Cancer Stem Cells. | Stem Cell Rev Rep | 2026 | https://conductscience.org/library/papers/41622398 | PubMed |
| 41422192 | Targeting cancer stem cell plasticity and tumor microenvironment crosstalk: a comprehensive review. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41422192 | PubMed |
| 41097779 | Liver-Specific Nanoparticle-Mediated Delivery and MMP-Triggered Release of Veratridine to Effectively Target Metastatic Colorectal Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097779 | PubMed |
| 40563292 | Decoding the NRF2-NOTCH Crosstalk in Lung Cancer-An Update. | Antioxidants (Basel) | 2025 | https://conductscience.org/library/papers/40563292 | PubMed |
| 40242505 | Nanotherapeutic strategies exploiting biological traits of cancer stem cells. | Bioact Mater | 2025 | https://conductscience.org/library/papers/40242505 | PubMed |
| 40229384 | Multifaceted roles of OCT4 in tumor microenvironment: biology and therapeutic implications. | Oncogene | 2025 | https://conductscience.org/library/papers/40229384 | PubMed |
| 40142941 | Targeting Cancer Stemness Using Nanotechnology in a Holistic Approach: A Narrative Review. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40142941 | PubMed |
| 39204369 | Novel Anti-Cancer Stem Cell Compounds: A Comprehensive Review. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/39204369 | PubMed |
| 38929532 | The Role of Epithelial Cell Adhesion Molecule Cancer Stem Cell Marker in Evaluation of Hepatocellular Carcinoma. | Medicina (Kaunas) | 2024 | https://conductscience.org/library/papers/38929532 | PubMed |
| 38612758 | The MDM2-p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612758 | PubMed |
| 38612715 | Hinokitiol Inhibits Breast Cancer Cells In Vitro Stemness-Progression and Self-Renewal with Apoptosis and Autophagy Modulation via the CD44/Nanog/SOX2/Oct4 Pathway. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612715 | PubMed |
| 38254735 | Harnessing Sulforaphane Potential as a Chemosensitizing Agent: A Comprehensive Review. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38254735 | PubMed |
| 37446085 | Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37446085 | PubMed |
Genes79
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36768445
GET https://conductscience.org/api/papers/v1/36768445/references?page=2